p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
Open Access
- 5 December 2005
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 118 (9), 2262-2268
- https://doi.org/10.1002/ijc.21608
Abstract
Lymph node (LN) status is an important prognostic factor in melanoma patients. p16 expression and proliferation rate (MIB‐1) of primary melanomas have been suggested as a marker of metastatic potential. In this study, the correlation of p16 expression and the proliferation rate (MIB‐1) with LN status and tumor‐specific survival was investigated in primary melanomas. MIB‐1 and p16 expression were analyzed by immunohistochemistry in 64 patients with primary cutaneous melanoma. Thirty four nevi were used as control. All patients underwent sentinel lymph node staging. Three different p16 staining patterns were observed: a combination of nuclear and cytoplasmic staining, only cytoplasmic staining and absence of p16 expression. All 34 nevi displayed a nuclear and cytoplasmic p16 staining, whereas p16 was negative in 14 of 64 (22%) melanomas. The level of p16 expression gradually decreased from benign nevi to melanoma without metastasis to melanoma with metastasis. There was a significant correlation between cytoplasmic p16 expression and absence of metastasis (p < 0.05). Death of disease correlated with absence of p16 immunostaining (p = 0.01). MIB‐1 expression was not associated with survival. These results confirm the relevance of p16 expression as a prognostic marker in melanoma patients. In addition, it was shown that cytoplasmic immunostaining for p16 in primary melanoma might serve as a predictor of the LN status. Therefore, immunohistochemical evaluation for p16 expression is of potential value for treatment planning in melanoma surgery.Keywords
This publication has 42 references indexed in Scilit:
- Indications for Lymphatic Mapping and Sentinel Lymphadenectomy in Patients with Thin Melanoma (Breslow Thickness ≤1.0 mm)Annals of Surgical Oncology, 2004
- Baseline staging in cutaneous malignant melanomaBritish Journal of Dermatology, 2004
- Electron microscopy evidence that cytoplasmic localization of the p16INK4A“nuclear” cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomasBiotechnic & Histochemistry, 2004
- Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucoseBritish Journal of Dermatology, 1995
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancersNature, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous MelanomaAnnals of Surgery, 1970